CNBX Pharmaceuticals Inc. (CNBX) Profit After Tax (2011 - 2026)

CNBX Pharmaceuticals (CNBX) has 16 years of Profit After Tax data on file, last reported at -$154165.0 in Q2 2026.

• Quarterly Profit After Tax fell 158.12% year-over-year to -$154165.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was -$462091.0 (down 105.88% YoY) and the FY2025 annual result came in at -$313976.0, up 54.84% from the prior year.
• Profit After Tax fell to -$154165.0 in Q2 2026, from -$44098.0 in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$34352.0 in Q4 2024 to a low of -$2.6 million in Q1 2023.
• A 5-year average of -$470418.9 and a median of -$154427.5 in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax jumped 88.21% — and 2025, when it tumbled 231.04%.
• Tracing CNBX's Profit After Tax over 5 years: stood at -$417539.0 in 2022, then jumped by 57.24% to -$178523.0 in 2023, then jumped by 80.76% to -$34352.0 in 2024, then plunged by 231.04% to -$113719.0 in 2025, then plunged by 35.57% to -$154165.0 in 2026.
• The last three Profit After Tax figures came in at -$154165.0 (Q2 2026), -$44098.0 (Q1 2026), and -$113719.0 (Q4 2025), per Business Quant data.